Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage
biotechnology company committed to discovering and delivering the
next generation of precision cancer medicines, reported its
financial results for the third quarter ended September 30, 2022,
and provided business highlights.
“We have made significant progress advancing our pipeline of
synthetic lethal therapies, including the recent expansion of
clinical trial sites for TNG908, our lead PRMT5 program, to include
France, and the declaration of TNG348 as a development candidate
for our USP1 program,” said Barbara Weber, M.D., President and
Chief Executive Officer of Tango Therapeutics. “In addition, we are
very pleased to announce the appointment of Ron Weitzman, M.D. as
our Chief Medical Officer. Dr. Weitzman has extensive experience in
oncology clinical development, including both early and full
development in solid tumors and hematologic malignancies, bringing
expertise and leadership as we continue to progress our
pipeline.”
Recent Business Highlights
Pipeline Update
TNG908, a novel synthetic lethal PRMT5
inhibitor
- Enrollment is ongoing in the dose
escalation phase of the TNG908 phase 1/2 trial.
- A CTA for TNG908 was approved by the
ANSM in France during the fourth quarter of 2022.
- TNG908 is a synthetic lethal inhibitor
of PRMT5 (protein arginine methyl transferase 5) that works
selectively in cancer cells with MTAP (methylthioadenosine
phosphorylase) deletion.
- MTAP deletions occur in approximately
10%-15% of all human cancers, including non-small cell lung cancer,
mesothelioma, cholangiocarcinoma and glioblastoma.
TNG260, a first-in-class CoREST complex
inhibitor
- The Company disclosed the target of
TNG260 as the CoREST complex. The CoREST complex (Co-repressor of
Repressor Element-1 Silencing Transcription) plays a major role in
regulating the expression of immunomodulatory proteins.
- Inhibition of the CoREST complex by
TNG260 reverses anti-PD1 resistance driven by STK11 mutations in
preclinical models.
- The Company expects to file an
Investigational New Drug (IND) application for this program in the
first half of 2023.
- STK11 mutations occur in approximately
15% of non-small cell lung, 15% of cervical, 10% of carcinoma of
unknown primary, 5% of breast and 3% of pancreatic cancers, among
others.
TNG348, a novel USP1 inhibitor
- The Company declared TNG348 a
development candidate for the USP1 program (ubiquitin-specific
protease 1) in 4Q 2022, which is being developed for the treatment
of BRCA1 and BRCA2-mutant cancers. The Company expects to file an
IND for TNG348 in 2023.
- In vivo preclinical studies of USP1
inhibition have shown single agent efficacy in BRCA1 and
BRCA2-mutant cell-line and patient derived xenografts, including
those that are intrinsically resistant to PARP inhibition. These
preclinical data further demonstrate that TNG348 is synergistic
with PARP inhibition across a panel of human ovarian and breast
cancer cell lines, including both PARP inhibitor resistant and
sensitive lines.
- BRCA1/2 mutations are present in
approximately 15% of ovarian, 10% of breast, 5% of endometrial and
5% of pancreatic cancers, among others.
Leadership Update
The Company strengthened its management team with the
appointment of Aaron (Ron) Weitzman, M.D., F.A.C.P. as Chief
Medical Officer. Dr. Weitzman brings more than 20 years of
experience in the biopharmaceutical industry. Dr. Weitzman has
served as Vice President of Clinical Development at Exelixis, where
he oversaw the global development of CABOMETYX®. He also had senior
clinical positions at Genentech, Novartis, and Eli Lilly and
Company, where he played key roles in the development of AVASTIN®
and TASIGNA®. Dr. Weitzman obtained his M.D. from the Medical
School at the University of Western Ontario, Canada. He completed
his medical residency at Mount Sinai Medical Center and completed
his clinical fellowship in Medical Oncology at
Columbia-Presbyterian Medical Center in New York City.
Scientific Presentations
Society for Immunotherapy of Cancer (SITC)
37th Annual Meeting, November
8-12, 2022, Boston, MA
- The Company presented four posters and
disclosed the target of TNG260, a first-in-class CoREST inhibitor
for the treatment of STK11-mutant cancers. Preclinical data
presented provide strong evidence that TNG260 reverses the immune
evasion caused by STK11 mutations, with the combination of TNG260
and α-PD1 driving complete tumor regressions in STK11-mutant
syngeneic xenografts.
- Additional posters highlighted the
potential of the proprietary discovery platform to identify novel
immune evasion targets for future development.
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
Symposium, October 26-28, 2022, Barcelona, Spain
- The Company presented three preclinical
posters on PRMT5 inhibitors, TNG908 and TNG462, highlighting the
potential of this program to address the high unmet need in
MTAP-deleted cancers.
Upcoming Milestones
- Initial safety and efficacy data is
expected from the Phase 1/2 clinical trial of TNG908, a synthetic
lethal PRMT5 inhibitor, in patients with MTAP-deleted solid tumors
during the first half of 2023.
- The IND filing for TNG462, a
next-generation MTA-cooperative PRMT5 inhibitor, is on track for
the first half of 2023.
- The IND filing for TNG260, a
first-in-class CoREST inhibitor, is on track for the first half of
2023.
- The IND filing for TNG348, a novel USP1
inhibitor that is being developed for treatment of BRCA1 and
BRCA2-mutant cancers, is on track for 2023.
Financial Results
As of September 30, 2022, the Company held $393.3 million
in cash, cash equivalents and marketable securities, which the
Company believes to be sufficient to fund operations into 2025.
Collaboration revenue was $6.9 million for the three months
ended September 30, 2022, compared to $6.8 million for the
same period in 2021, and $18.4 million for the nine months ended
September 30, 2022 compared to $20.3 million for the same
period in 2021. The year-to-date decrease was due to lower research
costs incurred under the Gilead collaboration during the nine
months ended September 30, 2022 resulting in lower
collaboration revenue recognized.
There was no license revenue for the three and nine months ended
September 30, 2022, compared to $0.0 and $11.0 million for the
three and nine months ended September 30, 2021, respectively.
The $11.0 million of license revenue recognized during the nine
months ended September 30, 2021 is the direct result of Gilead
licensing a program for $11.0 million during the second quarter of
2021.
Research and development expenses were $28.7 million for the
three months ended September 30, 2022, compared to $21.9
million for the same period in 2021, and $76.8 million for the nine
months ended September 30, 2022 compared to $56.0 million for
the same period in 2021. The change is primarily due to increased
spend relating to the advancement of the TNG462 and TNG260 programs
and personnel-related costs.
General and administrative expenses were $8.1 million for the
three months ended September 30, 2022, compared to $4.4
million for the same period in 2021, and $22.1 million for the nine
months ended September 30, 2022 compared to $11.5 million for
the same period in 2021. The change was primarily due to increases
in personnel-related costs.
Net loss for the three months ended September 30, 2022 was
$29.1 million, or $0.33 per share, compared to a net loss of $19.6
million, or $0.28 per share, in the same period in 2021. Net loss
for the nine months ended September 30, 2022 was $79.1
million, or $0.90 per share, compared to a net loss of $36.2
million, or $0.68 per share, in the same period in 2021.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company
dedicated to discovering novel drug targets and delivering the next
generation of precision medicine for the treatment of cancer. Using
an approach that starts and ends with patients, Tango leverages the
genetic principle of synthetic lethality to discover and develop
therapies that take aim at critical targets in cancer. This
includes expanding the universe of precision oncology targets into
novel areas such as tumor suppressor gene loss and their
contribution to the ability of cancer cells to evade immune cell
killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered
forward-looking statements. Forward-looking statements generally
relate to future events, Tango’s future operating performance and
goals, the anticipated benefits of therapies and combination
therapies (that include a Tango pipeline product), expectations,
beliefs and development objectives for Tango’s product pipeline and
clinical trials. In some cases, you can identify forward-looking
statements by terminology such as “may”, “should”, “expect”,
“intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”,
“predict”, “potential” or “continue”, or the negatives of these
terms or variations of them or similar terminology. For example,
statements concerning the following include or constitute
forward-looking statements: the Company believes its cash, cash
equivalents and marketable securities are sufficient to fund
operations into 2025; the Company expects to have initial safety
and efficacy data in connection with the TNG908 Phase 1/2 clinical
trial in the 1H 2023; TNG260 is a first-in-class, CoREST inhibitor
that has reversed anti-PD1 resistance driven by STK11 mutations in
preclinical models; the Company plans to file INDs for TNG462 and
TNG260 in the first half of 2023; the Company expects to file an
IND for TNG348 in 2023; the Company has the opportunity to
potentially expand the benefits of precision oncology to additional
genetically defined cancers, such as lung cancer and glioblastoma,
where a significant need for new options remains; the potential of
the Company’s proprietary discovery platform to identify synthetic
lethal targets for future development; the potential of the
Company’s PRMT5 therapies to address the high unmet need in
MTAP-deleted cancers; the indications expected to be included in
Company clinical trials; the potential applicability of synthetic
lethal drugs targeting across a range of cancer types; the expected
benefits of the Company's development candidates and other product
candidates; and the expected timing of: (i) development candidate
declaration for certain targets, (ii) initiating IND-enabling
studies; (iii) filing INDs; (iv) clinical trial initiation and (v)
disclosing initial and final clinical trial results. Such
forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially
from those expressed or implied by such forward looking statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by Tango and its
management, are inherently uncertain. New risks and uncertainties
may emerge from time to time, and it is not possible to predict all
risks and uncertainties. Factors that may cause actual results to
differ materially from current expectations include, but are not
limited to: Tango has limited experience conducting clinical trials
(and will rely on a third party to operate its clinical trials) and
may not be able to commence the clinical trial (including opening
clinical trial sites and enrolling and dosing an adequate number of
clinical trial participants) when expected and may not generate
results (including final or initial safety and efficacy data) in
the anticipated timeframe (or at all); benefits of product
candidates seen in preclinical analyses may not be evident when
tested in clinical trials or when used in broader patient
populations (if approved for commercial sale); the benefits of
Tango pipeline products, development candidates and potential
combination therapies that are seen in pre-clinical experiments may
not be present in clinical trials or in use commercially or may not
be safe and/or effective in humans; Tango has a limited operating
history and has not generated any revenue to date from product
sales, and may never become profitable; other companies may be able
to identify and develop product candidates more quickly than the
Company and commercially introduce the product prior to the
Company; the Company’s proprietary discovery platform is novel and
may not identify any synthetic lethal targets for future
development; the Company may not be able to identify development
candidates on the schedule it anticipates due to technical,
financial or other reasons; the Company may not be able to file
INDs for development candidates on time, or at all, due to
technical or financial reasons or otherwise; the Company may
utilize cash resources more quickly than anticipated; Tango will
need to raise capital in the future and if we are unable to raise
capital when needed or on attractive terms, we would be forced to
delay, scale back or discontinue some of our development programs
or future commercialization efforts; we may be unable to advance
our preclinical development programs into and through the clinic
for safety or efficacy reasons or commercialize our product
candidates or we may experience significant delays in doing so as a
result of factors beyond Tango’s control; the Company may not be
able to realize the benefits of fast track designation (and such
designation may not advance any anticipated approval timelines);
Tango’s approach to the discovery and development of product
candidates is novel and unproven, which makes it difficult to
predict the time, cost of development, and likelihood of
successfully developing any products; Tango may not identify or
discover additional product candidates or may expend limited
resources to pursue a particular product candidate or indication
and fail to capitalize on product candidates or indications that
may be more profitable or for which there is a greater likelihood
of success; our products candidates may cause adverse or other
undesirable side effects (or may not show requisite efficacy) that
could, among other things, delay or prevent regulatory approval;
our dependence on third parties for conducting clinical trials and
producing drug product; our ability to obtain and maintain patent
and other intellectual property protection for our technology and
product candidates or the scope of intellectual property protection
obtained is not sufficiently broad; and delays and other impacts on
product development and clinical trials from the COVID-19 pandemic.
Additional information concerning risks, uncertainties and
assumptions can be found in Tango’s filings with the SEC, including
the risk factors referenced in Tango’s Annual Report on Form 10-K
for the fiscal year ended December 31, 2021, as supplemented and/or
modified by its most recent Quarterly Report on Form 10-Q. You
should not place undue reliance on forward-looking statements in
this presentation, which speak only as of the date they are made
and are qualified in their entirety by reference to the cautionary
statements herein. Tango specifically disclaims any duty to update
these forward-looking statements.
Investor Contact:Sam Martin/Andrew VulisArgot
Partnerstango@argotpartners.com
Media Contact:Joshua R. Mansbach Argot Partners
tango@argotpartners.com
Consolidated Statements of
Operations(In thousands, except share and per
share data)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Collaboration revenue |
|
$ |
6,920 |
|
|
$ |
6,787 |
|
|
$ |
18,449 |
|
|
$ |
20,326 |
|
License
revenue |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
11,000 |
|
Total revenue |
|
$ |
6,920 |
|
|
$ |
6,787 |
|
|
$ |
18,449 |
|
|
$ |
31,326 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
28,744 |
|
|
|
21,923 |
|
|
|
76,815 |
|
|
|
56,002 |
|
General and administrative |
|
|
8,099 |
|
|
|
4,433 |
|
|
|
22,138 |
|
|
|
11,530 |
|
Total operating expenses |
|
|
36,843 |
|
|
|
26,356 |
|
|
|
98,953 |
|
|
|
67,532 |
|
Loss
from operations |
|
|
(29,923 |
) |
|
|
(19,569 |
) |
|
|
(80,504 |
) |
|
|
(36,206 |
) |
Other
income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
350 |
|
|
|
91 |
|
|
|
865 |
|
|
|
299 |
|
Other income (expense), net |
|
|
523 |
|
|
|
(50 |
) |
|
|
526 |
|
|
|
(167 |
) |
Total other income, net |
|
|
873 |
|
|
|
41 |
|
|
|
1,391 |
|
|
|
132 |
|
Loss
before income taxes |
|
|
(29,050 |
) |
|
|
(19,528 |
) |
|
|
(79,113 |
) |
|
|
(36,074 |
) |
Provision for income taxes |
|
|
- |
|
|
|
(62 |
) |
|
|
(3 |
) |
|
|
(115 |
) |
Net
loss |
|
$ |
(29,050 |
) |
|
$ |
(19,590 |
) |
|
$ |
(79,116 |
) |
|
$ |
(36,189 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
per common share – basic and diluted |
|
$ |
(0.33 |
) |
|
$ |
(0.28 |
) |
|
$ |
(0.90 |
) |
|
$ |
(0.68 |
) |
Weighted
average number of common shares outstanding – basic and
diluted |
|
|
87,892,195 |
|
|
|
70,160,663 |
|
|
|
87,868,081 |
|
|
|
53,397,557 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Balance
Sheets(In thousands)
|
|
September 30,2022 |
|
|
December 31,2021 |
|
Assets |
|
|
|
|
|
|
Current
assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
100,312 |
|
|
$ |
142,745 |
|
Marketable securities |
|
|
292,981 |
|
|
|
342,510 |
|
Accounts receivable |
|
|
2,000 |
|
|
|
2,000 |
|
Restricted cash |
|
|
567 |
|
|
|
567 |
|
Prepaid expenses and other current assets |
|
|
5,814 |
|
|
|
4,516 |
|
Total current assets |
|
|
401,674 |
|
|
|
492,338 |
|
Property
and equipment, net |
|
|
11,296 |
|
|
|
4,832 |
|
Operating lease right-of-use assets |
|
|
47,757 |
|
|
|
1,254 |
|
Restricted cash, net of current portion |
|
|
3,423 |
|
|
|
1,712 |
|
Other
assets |
|
|
6 |
|
|
|
19 |
|
Total assets |
|
$ |
464,156 |
|
|
$ |
500,155 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
6,314 |
|
|
$ |
3,226 |
|
Accrued expenses and other current liabilities |
|
|
15,752 |
|
|
|
9,887 |
|
Operating lease liabilities |
|
|
781 |
|
|
|
1,503 |
|
Deferred revenue |
|
|
28,475 |
|
|
|
26,022 |
|
Income tax payable |
|
|
— |
|
|
|
52 |
|
Total current liabilities |
|
|
51,322 |
|
|
|
40,690 |
|
Operating lease liability, net of current portion |
|
|
39,947 |
|
|
|
— |
|
Deferred revenue, net of current portion |
|
|
99,815 |
|
|
|
114,718 |
|
Total liabilities |
|
|
191,084 |
|
|
|
155,408 |
|
Total stockholders’ equity |
|
|
273,072 |
|
|
|
344,747 |
|
Total liabilities and stockholders’ equity |
|
$ |
464,156 |
|
|
$ |
500,155 |
|
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024